Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.19)
# 869
Out of 4,829 analysts
170
Total ratings
41.98%
Success rate
0.51%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRRO Korro Bio | Initiates: Overweight | $74 | $15.98 | +363.08% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.60 | +51.52% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $16.81 | +66.57% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $4.37 | +975.51% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.67 | +498.80% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $10.34 | +93.42% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $28.30 | +267.49% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.66 | +1,225.30% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $20.08 | +178.88% | 3 | Nov 8, 2024 | |
| ETNB 89bio | Maintains: Strong Buy | $53 → $49 | $8.11 | +504.19% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $1.59 | +780.50% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $103.82 | -10.42% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $22.49 | +202.36% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $17.52 | +505.02% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $3.53 | +324.93% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $12.56 | +345.86% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $78 → $64 | $45.57 | +40.44% | 18 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.38 | +4,565.42% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $8.55 | +566.67% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.24 | +1,674.19% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.54 | +1,003.90% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $7.00 | +400.00% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $32.17 | +18.12% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $29.33 | +142.07% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.10 | +354.55% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $20.03 | +89.72% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $11.59 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.28 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $124.40 | - | 2 | Apr 23, 2020 |
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $15.98
Upside: +363.08%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.60
Upside: +51.52%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $16.81
Upside: +66.57%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $4.37
Upside: +975.51%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.67
Upside: +498.80%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $10.34
Upside: +93.42%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $28.30
Upside: +267.49%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.66
Upside: +1,225.30%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $20.08
Upside: +178.88%
89bio
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $8.11
Upside: +504.19%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.59
Upside: +780.50%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $103.82
Upside: -10.42%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $22.49
Upside: +202.36%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $17.52
Upside: +505.02%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $3.53
Upside: +324.93%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $12.56
Upside: +345.86%
Dec 19, 2023
Maintains: Strong Buy
Price Target: $78 → $64
Current: $45.57
Upside: +40.44%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.38
Upside: +4,565.42%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $8.55
Upside: +566.67%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.24
Upside: +1,674.19%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.54
Upside: +1,003.90%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $7.00
Upside: +400.00%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $32.17
Upside: +18.12%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $29.33
Upside: +142.07%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.10
Upside: +354.55%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $20.03
Upside: +89.72%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $11.59
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.28
Upside: -
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $124.40
Upside: -